Reinilde Heyrman
Chief Tech/Sci/R&D Officer bij MEDPACE HOLDINGS, INC.
Profiel
Reinilde Heyrman is currently the Chief Medical Officer at Medpace Holdings, Inc. She previously worked as the Chief Clinical Development Officer at Ikaria, Inc. and as the Secretary, Chief Clinical Development Officer & VP at Bellerophon Therapeutics, Inc. Heyrman earned a doctorate degree from the University of Antwerp.
Actieve functies van Reinilde Heyrman
| Bedrijven | Functie | Begin |
|---|---|---|
| MEDPACE HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01-09-2017 |
Eerdere bekende functies van Reinilde Heyrman
| Bedrijven | Functie | Einde |
|---|---|---|
| IKARIA, INC. | Corporate Officer/Principal | - |
| BELLEROPHON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Reinilde Heyrman
| University of Antwerp | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| MEDPACE HOLDINGS, INC. | Commercial Services |
| Bedrijven in privébezit | 1 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
